CTOs on the Move

Accretive Health

www.accretivehealth.com

 
Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes. Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details
Jack Brock
Chief Information Officer Profile

Similar Companies

AIDS Commnty Rsrch Consortium

AIDS Commnty Rsrch Consortium is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VisualMED Clinical Solutions

VisualMED Clinical Solutions Corp. is a Outremont, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.

Celestiallabs

Celestiallabs Inc. is a Hoffman Estates, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xeridiem

Xeridiem is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.